{"filing":{"accession_number":"0001171843-26-005109","cik":"0000353278","ticker":"NONOF","company_name":"NOVO NORDISK A S","form":"6-K","filing_date":"2026-07-31","report_date":"2026-07-31","primary_document":"f6k_073126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/353278/000117184326005109/f6k_073126.htm"},"events":[{"id":22325,"run_id":20188,"accession_number":"0001171843-26-005109","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces negative results from the ZEUS phase 3 cardiovascular trial of ziltivekimab, which failed to meet its primary endpoint (MACE risk reduction) despite achieving target biological engagement. The company explicitly states this will result in \"a non-cash impairment charge in Q3 2026,\" indicating a material financial consequence. While the impairment itself is financial, the core event is the failure of a major clinical development program, which is an operational/strategic matter affecting the company's R\u0026D pipeline and future product prospects.","company_name":"NOVO NORDISK A S","ticker":"NONOF","filing_date":"2026-07-31","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":22241,"accession_number":"0001171843-26-005109","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces negative results from the ZEUS phase 3 cardiovascular trial of ziltivekimab, which failed to meet its primary endpoint (MACE risk reduction) despite achieving target biological engagement. The company explicitly states this will result in \"a non-cash impairment charge in Q3 2026,\" indicating a material financial consequence. While the impairment itself is financial, the core event is the failure of a major clinical development program, which is an operational/strategic matter affecting the company's R\u0026D pipeline and future product prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-08-01T00:02:35.253792+00:00","company_name":"NOVO NORDISK A S","ticker":"NONOF","filing_date":"2026-07-31"}]}